352208-32-3

Basic information

• Product Name: 4-[3-(3-tert-butyl-5-methoxy-2-methoxymethoxy-phenyl)-1-naphthalen-1-yl-ureido]-butyric acid ethyl ester
• Synonyms: 4-[3-(3-tert-butyl-5-methoxy-2-methoxymethoxy-phenyl)-1-naphthalen-1-yl-ureido]-butyric acid ethyl ester
• CAS NO: 352208-32-3
• Molecular Weight: 522.642
• Mol File: 352208-32-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[3-(3-tert-butyl-5-methoxy-2-methoxymethoxy-phenyl)-1-naphthalen-1-yl-ureido]-butyric acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(3-tert-butyl-5-methoxy-2-methoxymethoxy-phenyl)-1-naphthalen-1-yl-ureido]-butyric acid ethyl ester(352208-32-3)
• EPA Substance Registry System: 4-[3-(3-tert-butyl-5-methoxy-2-methoxymethoxy-phenyl)-1-naphthalen-1-yl-ureido]-butyric acid ethyl ester(352208-32-3)

Safety Data

• Hazardous Substances Data: 352208-32-3(Hazardous Substances Data)

Upstream product

• 725744-48-9 ethyl 4-[N-benzyloxycarbonyl-N-(1-naphthyl)amino]butyrate 
• 6336-03-4 naphthalen-1-ylcarbamic acid benzyl ester 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 195314-33-1 3-tert-butyl-5-methoxy-2-methoxymethoxyaniline 
• 74297-35-1 ethyl 4-(naphthalen-1-ylamino)butanoate 

Relevant articles and documents

Novel hydroxyphenylurea dual inhibitor against Acyl-CoA: Cholesterol acyltransferase (ACAT) and low density lipoprotein (LDL) oxidation as antiatherosclerotic agent

Novel hydroxyphenylurea derivatives were synthesized and their inhibitory potency evaluated against acyl-CoA: cholesterol acyltransferase ACAT. Quantitative structure-activity relationship analysis revealed that their ACAT inhibitory activities were controlled by the hydrophobicity of the whole molecule, the substitution pattern of urea moiety, and the existence of carboxylic acid. The derivatives with strong activities inhibited foam cell formations. Moreover, these compounds showed antioxidative effects against low density lipoprotein LDL, owing to their characteristic 3-tert-butyl-2-hydroxy-5-methoxyphenyl substructure. Based on the mechanism of atherosclerosis generation, this hydroxyphenylurea-type dual inhibitor against both ACAT and LDL oxidation is expected to be a promising drug for atherosclerosis. Copyright